HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment of Paget's disease of bone with alendronate.

Abstract
In summary, the clinical efficacy studies provide clear evidence that treatment with oral alendronate markedly suppresses bone turnover and produces clinical improvement in pagetic patients. Serum alkaline phosphatase was greatly decreased by treatment, and the response to alendronate was superior to that observed for currently available therapies such as etidronate and calcitonin, which usually reduce alkaline phosphatase, on average, by 40%-50%. Alendronate also markedly reduced urinary resorption markers and induced radiologic improvement of pagetic osteolysis. A majority of alendronate-treated patients normalized their serum alkaline phosphatase by month 6. This observation is likely to be relevant to the duration of response to treatment, as previous studies have shown that the degree of suppression of alkaline phosphatase after antiresorptive treatment correlates with the duration of remission. Therefore, patients who responded to treatment with alendronate, especially those who normalized their alkaline phosphatase levels, are likely to maintain the biochemical remission for several years. Indeed, preliminary unpublished data seem to indicate that alendronate is capable of producing long-term biochemical remission in the majority of patients. In addition to its efficacy, the safety and tolerability profile of alendronate 40 mg/day was very favorable and, overall, comparable to that of placebo.
AuthorsA Lombardi
JournalBone (Bone) Vol. 24 Issue 5 Suppl Pg. 59S-61S (May 1999) ISSN: 8756-3282 [Print] United States
PMID10321931 (Publication Type: Clinical Trial, Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
Chemical References
  • Alkaline Phosphatase
  • Etidronic Acid
  • Alendronate
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Alendronate (adverse effects, therapeutic use)
  • Alkaline Phosphatase (blood)
  • Bone Resorption (prevention & control)
  • Etidronic Acid (therapeutic use)
  • Female
  • Gastrointestinal Diseases (chemically induced)
  • Humans
  • Male
  • Middle Aged
  • Osteitis Deformans (drug therapy, enzymology)
  • Osteolysis (drug therapy)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: